Osteoporosis Drugs, Fracture Reduction, and the Drug-Holiday Question

Bisphosphonates lower the risk of fragility fractures, including hip fractures, and that benefit dwarfs the rare harm most people worry about: the atypical femur fracture. In a 2020 New England Journal of Medicine analysis of women treated in a large California health system, roughly 149 hip fractures were prevented for every two bisphosphonate-associated atypical femur fractures over three years among White women. That lopsided arithmetic, together with the fact that atypical-fracture risk climbs the longer someone stays on the drug and drops quickly once they stop, is the reason clinicians talk about a drug holiday. A holiday is a scheduled moment to weigh benefit against risk again, not a fixed calendar rule that fits everyone.

What these drugs are asked to do

Osteoporosis is silent until a bone breaks. It thins the skeleton over years, most commonly after menopause, and the fractures it produces at the hip and spine carry real consequences for mobility and independence. Bisphosphonates work by slowing the cells that resorb bone, which lets bone density stabilize or improve and lowers the chance of the fractures that matter most. Large randomized trials established that these agents reduce both vertebral and hip fractures, and the 2016 task force report of the American Society for Bone and Mineral Research summarizes that evidence base as the foundation for treating people at high fracture risk.

The benefit is not abstract. A hip fracture in an older adult can end independent living, and it carries meaningful excess mortality in the year that follows. When a drug reliably prevents that event, the bar for accepting a rare side effect is high.

The risk that draws the headlines

The atypical femur fracture is the harm that worries patients most, partly because it seems to invert the drug's purpose: a break in the thigh bone in someone taking a bone-strengthening medicine. These fractures are genuinely different from ordinary breaks. They occur below the hip joint, often with little or no trauma, sometimes preceded by weeks of thigh pain.

Black and colleagues quantified how the risk behaves. Compared with less than three months of use, the risk of an atypical femur fracture rose sharply with duration: a hazard ratio near 9 at three to five years, and above 40 after eight or more years of continuous use. The other half of that finding is more reassuring. Once bisphosphonates were stopped, the excess risk fell fast, by roughly half within about fifteen months and by about three-quarters beyond that. The risk is tied to ongoing, prolonged exposure, and it recedes when exposure ends.

The arithmetic that actually matters

A hazard ratio above 40 sounds alarming until you anchor it to absolute numbers. Atypical femur fractures are rare events, so multiplying a very small baseline by a large factor still yields a small count. That is why the study's head-to-head comparison is the number to hold onto. Over three years, the White women in the analysis saw about 149 hip fractures and 541 total clinical fractures prevented against two atypical fractures caused. The scale of prevention overwhelms the harm.

The balance was not identical for everyone. Women of Asian ancestry in the same study carried a higher atypical-fracture risk, so their comparison was narrower: about 91 hip fractures prevented against eight atypical fractures over three years. The benefit still pointed in the same direction, but the margin was tighter, which is exactly the kind of detail that should personalize a decision rather than drive a blanket policy. This is a working lesson in reading evidence: a frightening relative risk and a small absolute risk can describe the same fact, and only one of them tells you what to do.

Why a drug holiday is a question, not a rule

If risk rises with cumulative years and falls after stopping, then time on the drug is itself a variable to manage. That is the logic behind the drug holiday. The idea is to give bisphosphonates long enough to deliver their fracture protection, then pause and reassess rather than continue indefinitely by default.

The reassessment is individualized. The ASBMR task force framed a practical checkpoint: after roughly five years of oral therapy or three years of intravenous therapy, reconsider risk. People who remain at high risk, such as those with a very low hip bone-density score or a fracture during treatment, tend to benefit from continuing, a pattern seen in the long-term extensions of the alendronate and zoledronic acid trials. People whose risk has settled lower may reasonably pause, because oral bisphosphonates linger in bone and offer some residual protection for a time after the last dose. A holiday is not permanent; it is a period during which risk is monitored and treatment can resume.

Who even starts this conversation

None of this applies to someone who was never identified as being at risk. That is the role of screening. In January 2025 the US Preventive Services Task Force reaffirmed a Grade B recommendation for bone-density screening in women 65 and older, and in younger postmenopausal women at increased risk. Screening is what surfaces the people for whom the benefit-risk math is worth doing in the first place, and the Task Force found insufficient evidence to make the same recommendation in men.

How to read this as a patient

The durable takeaway is a habit of mind. Ask for absolute numbers, not only relative risk. Ask how a benefit and a harm change over time rather than treating either as fixed. And recognize that a decision to start, continue, or pause a medicine depends on an individual's fracture risk, ancestry, and response, which is why the same evidence supports different choices for different people. This article is educational and is not medical advice; decisions about osteoporosis treatment belong to a person and their own clinician.